Rigel licenses VEPPANU (vepdegestrant) from Arvinas/Pfizer; $70M upfront plus milestones

RIGEL PHARMACEUTICALS INC

Upfront payment of $70M, plus $15M on transition completion; total potential milestones up to $320M.
Tiered royalties on net sales from mid-teens to mid-twenties percent; sublicense revenue sharing.
Rigel gets exclusive worldwide rights to develop, manufacture, and commercialize VEPPANU.
VEPPANU approved in US for ER+/HER2- ESR1-mutated advanced/metastatic breast cancer.
Deal subject to HSR waiting period expiration or termination.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

RIGEL PHARMACEUTICALS INC entered into Agreement with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. valued at $70 million upfront payment, $15 million transition completion payment, up to $320 million in milest (effective 2026-05-11).

Action: entry
Agreement: license
Counterparty: Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc.
Value: $70 million upfront payment, $15 million transition completion payment, up to $320 million in milest
Effective: 2026-05-11

Exact text from the filing

On May 11, 2026, Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") entered into a License Agreement (the "Agreement") with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. (collectively, the "Licensors").

View on SEC.gov

301 material agreements filed in the last 30 days. Browse all material agreements →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001034842-26-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.